KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results.

Cynthia Levy, Palak J Trivedi, Kris V Kowdley, Stuart C Gordon, Christopher L Bowlus, Maria Carlota Londoño, Gideon M Hirschfield, Aliya Gulamhusein, Eric J Lawitz, John M Vierling, Marlyn J Mayo, Ira M Jacobson, Andreas E Kremer, Christophe Corpechot, David Jones, Peter Buggisch, Shuqiong Zhuo, Sarah Proehl, Carrie Heusner, Charles A McWherter, Daria B Crittenden, ASSURE Investigators

Am J Gastroenterol 121(5) 1140-53

PMID40553148
PMCIDPMC13127731
DOI10.14309/ajg.0000000000003603
发表日期2025-06-24
摘要

摘要

INTRODUCTION: The objective of these analyses was to evaluate interim data from the ongoing, open-label, long-term efficacy and safety ASSURE study of seladelpar, a selective peroxisome proliferator-activated receptor δ agonist, in primary biliary cholangitis. METHODS: Patients rolling over from the phase 3, randomized, placebo-controlled, 12-month RESPONSE study or with previous participation in earlier legacy seladelpar studies were enrolled. Interim evaluations included composite biochemical response (alkaline phosphatase <1.67 upper limit of normal, total bilirubin ≤ upper limit of normal, and alkaline phosphatase decrease ≥15%), pruritus numerical rating scale (NRS) change among patients with a baseline score ≥4, and safety. RESULTS: At interim cutoff, 337 patients were enrolled and received ≥1 seladelpar 10 mg dose: 54 placebo-treated and 104 seladelpar-treated from RESPONSE and 179 from legacy studies. The composite response rate at RESPONSE completion was 62% (79/128) with seladelpar and 20% (13/65) with placebo. After 12 months in ASSURE, among patients who rolled over from RESPONSE, response rates were 72% (21/29) in patients continuing seladelpar and 94% (15/16) in crossover seladelpar patients. In legacy trial patients, response rates were 73% (120/164) and 70% (69/99) after 12 and 24 months of treatment in ASSURE, respectively. The NRS decrease at RESPONSE completion in seladelpar-treated patients with baseline NRS ≥4 (-3.4) was maintained after 6 additional months of treatment (-3.8); changes were similar in crossover seladelpar (-3.8) and legacy patients (-3.5) after 6 months of treatment in ASSURE. No seladelpar-related serious adverse events were reported. DISCUSSION: Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。